The Efficacy of Silymarin as Adjuvant Therapy on Colorectal Cancer Patients Undergoing FOLFIRI Treatment

• Status: Completed
• Trial end date: 2020-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Primary objectives: Use both listed and relatively safe drug, Silymarin,s to improve the intestinal side effect of the patients undergoing FOLFIRI chemotherapy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital
• Treatments: Silymarin

Criteria

Inclusion Criteria:

1. The patient who is between 20 to 80 years old

2. The patient who is diagnosed metastatic colorectal cancer and received chemotherapy with FOLFIRI regimen

3. The female patient should not be pregnant or breast-feeding

4. The patient who has no severe co-morbidity, such as cardiovascular, cerebrovascular, malignant hypertension, renal and hepatobiliary disease.

5. The patient who has no associated drug allergy to this trial.

6. The patient who is in compliance with prescribed medication.

7. The patient who is willing to sign the permit of the clinical trial.

Exclusion Criteria:

1. The patients who do not meet the main inclusion criteria or are not willing to sign the permit.

2. The patient who has viral hepatitis or carrier with impaired liver function.